[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-acute":60},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,42,75,99,126,149,172,193,218,248,280,303,329,356,385,417,449,474,505,525,558,577,600,624,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644976","brief-postoperative-pain-management-intervention-meaning-making-amendment-100644976",false,"NCT07676500","Brief Postoperative Pain Management Intervention: Meaning Making Amendment","Brief Postoperative Pain Management Intervention for Knee and Hip Replacement Patients: Meaning Making Amendment","Inclusion Criteria:\n\n* Age ≥18,\n* Underwent joint arthroplasty of the knee or hip\n\nExclusion Criteria:\n\n* Inability to read English\n* Cognitive impairment preventing completion of study procedures","ALL","18 Years",{"count":20,"type":21},576,"ESTIMATED","INTERVENTIONAL",[24],"NA","This single-site, two-arm, parallel-group randomized controlled trial will enroll adults undergoing total knee or hip replacement surgery. Two days after surgery, participants will complete a brief guided mindful breathing practice delivered by text message and will then be randomized to receive either personalized meaning-making questions or implementation-focused questions. The trial will evaluate whether personalized meaning-making questions enhance the clinical effects of the mindfulness practice on acute pain, pain unpleasantness, anxiety, desire for pain medication.",[27,28],"Pain, Acute","Anxiety Acute","NOT_YET_RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":21},"2026-07-01",{"date":37,"type":21},"2027-09-30",{"name":39,"class":40},"University of Utah","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100544518","tens-analgesia-during-outpatient-urethral-bulking-for-stress-urinary-incontinence-100544518","NCT06369922","TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","Transcutaneous Electrical Nerve Stimulation Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","TENSUB","Inclusion Criteria:\n\n* • Women, Age ≥18 years\n\n  * Diagnosis of SUI\n  * Scheduled to undergo transurethral bulking in the office\n  * Able to read\u002Fwrite English\n\nExclusion Criteria:\n\n* • Cutaneous damage such as ulcers or broken skin on target treatment area\n\n  * Currently implanted cardiac pacemaker or defibrillator\n  * Pre-procedural use of opioids for pain management, less than 8 hours from last dose\n  * Participants with altered sensation below the umbilicus","FEMALE",{"count":52,"type":21},100,[24],"This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS.",[56,57,58,59,60],"Stress Incontinence Female","Urinary Incontinence","Urinary Incontinence,Stress","Pain","Pain Acute",[62,63,64],"TENS","pain","Transcutaneous Electrical Nerve Stimulation Analgesia","RECRUITING","2026-05-11",{"date":68,"type":33},"2026-05-13",{"date":70,"type":33},"2024-07-01",{"date":72,"type":21},"2027-06-01",{"name":74,"class":40},"University of Rochester",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100339160","early-phase-1-a-pilot-trial-of-disposable-nitrous-oxide-canisters-in-providing-pain-control-during-burn-dressing-changes-100339160","NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes","A Pilot Randomized Controlled Crossover Trial of the Effectiveness of Disposable Nitrous Oxide Canisters in Providing Improved Pain Control During Burn Dressing Changes.","Inclusion criteria\n\n* adult burn patients admitted to the Health Sciences Centre\n* total body surface area burned of 5-20%\n\nExclusion criteria\n\n* admitted to intensive care unit\n* unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand English or visually impaired)\n* medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5).\n* pregnant\n* physically unable to hold the canister\n* \\\u003C90% SaO2 on room air\n* face burn\n* pre-injury narcotics (relative exclusion)\n* use of IV ketamine\n* pre-existing lung injury",{"count":83,"type":21},30,[85],"EARLY_PHASE1","Improvements in burn care have resulted in increased survival. Despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. The traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.",[88,27],"Burns",[90],"burns, pain, dressing change, nitrous oxide",{"date":92,"type":33},"2026-05-14",{"date":94,"type":33},"2019-10-01",{"date":96,"type":21},"2029-12-01",{"name":98,"class":40},"University of Manitoba",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":41},"100547675","the-efficacy-of-acu-tens-as-an-adjunct-analgesic-during-usg-mva-100547675","NCT06411054","The Efficacy of Acu-TENS as an Adjunct Analgesic During USG-MVA","The Efficacy of Acupuncture-type Transcutaneous Electrical Nerve Stimulation as an Adjunct Analgesic in Reducing Pain During Ultrasound-guided Manual Vacuum Aspiration: A Prospective, Single- Blinded Two-arm Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Aged 18 or above;\n2. Patient diagnosed with first-trimester miscarriage, who is eligible for USG-MVA;\n3. Patient diagnosed with incomplete miscarriage after medical treatment;\n4. Willing to be randomized to receive acupuncture.\n\nExclusion criteria\n\na. Patient not eligible for USG-MVA i. Miscarriage \\> 12 weeks of gestation; or ii. Pregnancy of unknown origin; or iii. Known narrowing of the cervical canal; or iv. Multiple uterine fibroids; or v. Congenital uterine anomalies; or vi. Active pelvic infection; or vii. Bleeding disorder; or viii. Inability to tolerate pelvic examination; or ix. History of allergy to misoprostol\n\nb. Patient not eligible for acu-TENS i. Poor skin integrity at the acupuncture site, such as open wound, infections, unknown mass, bleeding tendency; or ii. Allergic to external alcohol; or iii. Emotionally unstable or tend to restlessness (to avoid tear-off of pads).\n\nc. Patient refusal",{"count":107,"type":21},108,[24],"Objectives: To prospectively evaluate the potential of acu-TENS to reduce the pain experienced by women undergoing ultrasound-guided manual vacuum aspiration (USG-MVA) and evaluate its safety profile.\n\nHypothesis to be tested: Does the use of acu-TENS reduce pain in women undergoing USG-MVA?\n\nDesign and subjects: A prospective randomized control trial will be carried out at the Department of Obstetrics and Gynaecology of the Prince of Wales Hospital. Women undergoing USG-MVA for the treatment of early pregnancy loss before 12 weeks of gestation will be randomized to receive acu-TENS (intervention group) or sham acu-TENS (control group) for pain control during USG-MVA. We will recruit 54 participants in each of the two arms, so a total of 108 patients will be recruited.\n\nStudy instruments: USG-MVA will be performed using a 60ml charged syringe (MedGyn Aspiration Kit) with a flexible curette attached to it. Transabdominal ultrasound during the MVA procedure will be performed using Mindray DC-80A Diagnostic Ultrasound System. Acu-TENS will be performed using MTR+ Myolito Multifunctional Stimulator (MTRP-00003).\n\nMain outcome measures: Primary outcome includes pain scores before, during and after USG-MVA. Secondary outcomes include (1) stress levels measured by heart rate, heart rate variability, blood pressure, State Trait Anxiety Inventory (STAI), and salivary cortisol; (2) anxiety level; (3) Surgeon's assessment on the patient co-operation score and patient intraoperative pain, (4) Client Satisfaction Questionnaire (CSQ8) and satisfaction score, and (5) any adverse events of acu-TENS.\n\nData analysis: Data analysis will be performed using the Statistical Packages of Social Sciences for Windows (SPSS, Inc).\n\nExpected results: We expect that acu-TENS will result in at least a 35% reduction in pain experienced by women undergoing USG-MVA.",[27],[112,113,114,115,116],"Manual vacuum aspiration","Ultrasound-guided","Acupuncture transcutaneous electrical nerve stimulation","Alternative medicine","Randomized controlled trial","2026-05-08",{"date":119,"type":33},"2026-05-12",{"date":121,"type":33},"2024-06-01",{"date":123,"type":21},"2027-08-31",{"name":125,"class":40},"Chinese University of Hong Kong",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100557563","variability-in-analgesic-response-to-ibuprofen-100557563","NCT06539741","Variability in Analgesic Response to Ibuprofen","Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Ability to take oral medication and be willing to adhere to the study treatment regimen\n4. Men and women greater than 18 years of age requiring extraction of at least one impacted mandibular third molar tooth (at least 50% covered with bone).\n5. Absence of other major medical problems or contraindications to surgery or study drugs.\n6. Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, Depo-Provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and a urine pregnancy test on the day of surgery, which must be negative at all time points.\n7. Has not ingested caffeine-containing products within 12 hours of surgery.\n8. All subjects must consent to a urine drug test at screening. Results must be negative (except for THC) unless the subject is on a stable dose of a non-analgesic drug for a legitimate medical purpose. A positive test for THC will be permitted and the frequency of use will be documented. A positive result will be reported to the subject.\n9. Does not consume more than 1 alcoholic beverage per day on average.\n10. Subjects must reach a level of at least moderate pain within four hours of surgery completion, with a pain score greater than or equal to 4 on a 0-10 numerical pain scale\n11. Subjects must be willing and able to complete safety and efficacy diaries.\n12. An escort must be available to pick up the subject at the end of at the end of the surgical\u002Fdosing visit (Visit #2).\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant or nursing a child.\n2. Subjects who have received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening.\n3. Subjects who are sensitive or allergic to ibuprofen, acetaminophen, or their components.\n4. Subjects who are sensitive or allergic to aspirin or other NSAIDs.\n5. Subjects who are sensitive or allergic to oxycodone or other opioids (excluding nausea and constipation).\n6. Presence of a serious medical condition (e.g. poorly controlled hypertension or diabetes, gastrointestinal disorders such as bleeding ulcer, coagulation or bleeding disorders, significantly impaired cardiac, renal, hepatic, respiratory, or thyroid function) that according to the investigator may interfere with interpretation of the study results or compromise the safety of a potential subject.\n7. Acute local infection at the time of surgery that could confound post-surgical evaluation.\n8. Use of any confounding prescription or non-prescription drug within 24 hours of the surgical procedure, including analgesics, sedating antihistamine, sedative, alcohol, or CNS\u002Fpsychotropic agents (i.e. sleep aids, benzodiazepines). Hormonal contraceptives, hormone replacement therapy (including males taking testosterone as a hormone replacement to treat a documented low testosterone level), or thyroid replacement hormones are allowed. Individuals taking other\u002Fadditional chronic stable medications can be considered on a case-by-case basis for inclusion in the study if agreed upon by judgment of the investigator.\n9. Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.\n10. Subjects who have a history of opioid use disorder or other substance use disorder, based upon history and judgment of the Investigator.\n11. Subjects who are unwilling to provide a blood sample for genetic analyses.\n12. Employees of the principal investigator, sub-investigators, or relative of an employee who is directly involved in this study.",true,{"count":135,"type":21},200,"OBSERVATIONAL","Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, are recommended as first-line treatment for post-surgical dental pain. However, there is variability in analgesic response, and some patients require supplemental opioids for adequate pain relief. The goal of this study is to identify the factors that contribute to the need for opioid after third molar extraction to help limit unnecessary opioid prescriptions in patients who will have good pain relief with ibuprofen alone.",[139,27],"Impacted Third Molar Tooth","2026-05-04",{"date":142,"type":33},"2026-05-06",{"date":144,"type":33},"2025-01-03",{"date":146,"type":21},"2027-09",{"name":148,"class":40},"University of Pennsylvania",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100635462","splinted-wrist-study-100635462","NCT07553000","Splinted Wrist Study","The Additional Pain Relieving Benefit of Using a Splint in Suspected Wrist Fractures in Adult Patients at an Emergency Department - a Randomized Controlled Trial.","Inclusion Criteria:\n\n* NRS 5-10\n* Suspected distal fracture of radius\n\nExclusion Criteria:\n\n* No X-ray veriefied fracture.",{"count":157,"type":21},120,[24],"Randomized clinical trial comparing SAM aluminium splint vs pain relief as usual in patients seeking emergency department care for suspected wrist fractures.",[161,162,27],"Wrist Injuries","Wrist Fracture","2026-04-24",{"date":165,"type":33},"2026-04-27",{"date":167,"type":33},"2022-12-14",{"date":169,"type":21},"2027-12-30",{"name":171,"class":40},"Region Skane",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":133,"sex":17,"minAge":178,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":41},"100517679","latinx-children-and-surgery-100517679","NCT06020677","Latinx Children and Surgery","Inclusion Criteria:\n\nChildren:\n\n1. Children age 2-7 who are scheduled to undergo outpatient surgery.\n2. Children of Latinx parents, who speak Spanish as a primary language and who may speak English\n3. Children whose health status is American Society of Anesthesiologists (ASA) physical status I-III will be recruited for this study. ASA status I refers to \"patients who are normal and healthy with no known systemic disease\". ASA status II refers to \"patients who have mild or well-controlled systemic diseases,\" such as non-insulin dependent diabetes, upper respiratory conditions, well-controlled asthma or allergies. ASA status III refers to patients who have moderate or severe systemic disease, which does limit their activities (e.g., stable angina or diabetes with systemic sequellae). This criteria was chosen as this group of children will typically undergo surgery in an outpatient setting. ASA status IV children will most likely undergo surgery in an inpatient setting and represents a much sicker population of children with different barriers.\n4. Only children who are in the normal range of development will be recruited for this study. This will be assessed by report from the parents at the time of recruitment. The rationale for excluding patients with developmental delay is that it is unknown whether parents manage their children's postoperative pain differently than in the general population. To generalize the findings to the general population, children with developmental delays will be excluded.\n\nExclusion Criteria:\n\n1. Children with health status defined by ASA status IV-V will be excluded from this study. ASA status IV refers to \"patients with an incapacitating systemic disease that is a constant threat to life\". ASA status V \"patients are considered moribund\".\n2. Children whose parents do not identify as Latinx will be excluded from this study.\n3. Children who are taking psychotropic or pain medications that affect emotion modulation will be excluded from this study because of the potential for confounding effects on pain.\n4. Children with current malignant or any other disease or pain condition will be excluded as this may impact postoperative pain and thus be a confounding variable.\n\nParent:\n\nInclusion Criteria:\n\n1\\. Latinx Parents of children who are enrolled in the study who speak Spanish as a primary language and who may speak English.\n\nExclusion Criteria:\n\n1. Parents who refuse to be part of the study.\n2. Parents who do not speak Spanish as the primary language.","2 Years","7 Years",{"count":157,"type":21},[24],"Over 60 million persons in the United States (US) identify themselves as Latinx and 25.6% are children under the age of 16.\n\nSurgical disparities for adults and children have been identified as a major problem in the US and can be experienced at multiple points along a patient's health care trajectory. Data from the investigator's center indicates that a substantial portion of Latinx children who undergo surgery experience high anxiety and postoperative pain as well as postoperative impairments in psychological and physical functioning as compared to White non-Latin children who undergo surgery. Recent growth in use of mobile devices provides us an opportunity to create low-cost mobile health (mHealth) behavioral interventions to reduce this disparity in surgical outcomes.\n\nIn a previous National Institutes of Health (NIH) award, the principal investigator (PI) developed and tested an evidence based mHealth tailored intervention (WebTIPS) that aims to prepare and be a companion of a child and their family during a surgical event. WebTIPS aims to enhance the recovery of the child in several ways such as reducing anxiety and pain and is based on information provision, modeling, and teaching of coping skills. WebTIPS, however, was developed and validated with a population of primarily White non-Latinx English-speaking children and their parents. Unfortunately, it is well established that mHealth interventions are significantly less effective when used with specific ethnic minorities unless they underwent a process of cultural adaptation. Over the past 4-years, the investigators have established multiple academic and community collaborations, conducted extensive participatory research with Latinx stakeholders and used the heuristic framework and a modified ecological validity model to culturally adapt WebTIPS. The culturally adapted intervention is called L-WebTIPS. The overall aim of this application is to reduce surgical disparities in a population of Latinx children undergoing surgery. The first phase of this application (R61) includes web programming of L-WebTIPS, and a feasibly randomized control trial (RCT) to test this intervention. The second phase (R33) includes a multi-center RCT which aims to determine the effectiveness of L-WebTIPS compared to attention control intervention in decreasing postoperative pain, opioids consumption and lowering anxiety in Latinx children undergoing outpatient surgery. Secondary aims of the R33 include examining the impact of L-WebTIPS on home-based clinical recovery parameters such as pain, analgesic requirements, new onset behavioral changes and return to normal daily activity in Latinx children undergoing outpatient surgery. The investigators also plan to determine if the use of L-WebTIPS reduces anxiety and improve experience among the parents of Latinx children undergoing surgery.\n\nFinally, the investigators plan to determine if the use of L-WebTIPS reduces anxiety and enhance experience among the parents of Latinx children undergoing surgery. The investigators submit that using a cultural adaption process for an existing validated intervention will accelerate the process of reducing surgical disparities and bringing an effective intervention to clinical settings and routine use.",[184,27],"Pain, Postoperative","2026-04-09",{"date":187,"type":33},"2026-04-14",{"date":189,"type":33},"2023-08-23",{"date":123,"type":21},{"name":192,"class":40},"University of California, Irvine",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":41},"100481942","impact-of-vitamin-c-on-opiod-consumption-after-an-emergency-department-visit-for-acute-musculoskeletal-pain-100481942","NCT05555576","Impact of Vitamin C on opioïd Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain","Impact of Vitamin C on the Reduction of Opioid Consumption After an Emergency Department Visit for Acute Musculoskeletal Pain: A Double-Blind Randomized Control Trial Protocol","Inclusion Criteria:\n\n1. Aged 18 and over;\n2. Treated in ED for acute musculoskeletal pain present for less than 2 weeks;\n3. Discharged with an opioid prescription;\n4. Speaks French or English.\n\nExclusion Criteria:\n\n1. Opioid use 1 month prior to the ED visit;\n2. Already taking vitamin C supplement;\n3. Active cancer;\n4. Treated for chronic pain;\n5. Treated for opioid use disorder;\n6. Unable to fill out diary or unavailable for follow-up;\n7. Any allergy, intolerance or sensitivity to milk (lactose) or morphine\n8. Treated with cyclosporin or coumadin\n9. Pregnant or lactating (dosage \\> 1,800 mg not recommended. For women of child-bearing age and sexually active in the past 3 months, a urine pregnancy test will be performed.)",{"count":201,"type":21},464,[24],"Recent evidence has shown that vitamin C has some analgesic properties and can therefore reduce opioids used during healing. Vitamin C analgesic effect has been explored mostly during the short-term postoperative context or in disease specific chronic pain prevention but not after acute musculoskeletal injuries, which are often seen in the emergency department (ED).\n\nThe study's primary aim is to compare the total morphine 5 mg equivalent pills consumed during a two-week follow-up between patients receiving vitamin C or a placebo after ED discharge for an acute musculoskeletal pain complaint.\n\nThe investigators will conduct a double-blind randomized placebo-controlled trial with 464 participants distributed in two arms, one group receiving 1 000 mg of vitamin C twice a day for 14 days and another one receiving a placebo. Participants will be ≥18 years of age, treated in ED for acute musculoskeletal pain present for less than 2 weeks, and discharged with an opioid prescription for home pain management. Total morphine 5 mg equivalent pills consumed during the two-week follow-up will be assessed via an electronic (or paper) diary. In addition, patients will report their daily pain intensity, pain relief, side effects, and other types of pain medication or other non-pharmacological approach (ice, heat, immobilization, etc.) used. Three months after the injury, participants will also be contacted to evaluate chronic pain development. The investigators hypothesized that vitamin C, compared to a placebo, will reduce opioid consumption during a 14-day follow-up for ED discharged patients treated for acute pain.",[27],[206,207,208,59],"Vitamin C","Opioids","Emergency department","2026-03-26",{"date":211,"type":33},"2026-03-31",{"date":213,"type":33},"2023-11-01",{"date":215,"type":21},"2026-12",{"name":217,"class":40},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100564219","blue-light-as-an-anti-inflammatory-and-analgesic-strategy-in-thoracic-trauma-100564219","NCT06626334","Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma","Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma: A Randomized Controlled Trial in Adults With Rib Fractures","BLAASTT","Inclusion Criteria:\n\n* Age greater than or equal to 18 years\n* Admitted to a single large academic level I trauma center (Presbyterian\u002FMontefiore hospital) within the first 48 hours of traumatic injury\n* Greater than or equal to 1 acute rib fracture\n* Pain related to rib fracture(s), by one or more of the following criteria: 1. Pain \\>\u002F= 4\u002F10 at rest, 2. Pain \\>\u002F= 4\u002F10 with incentive spirometer (IS) use, and\u002For 3. Inspiratory volume \\\u003C 1000 cc\n* Anticipated length of stay greater than or equal to 48 hours\n* Alert, with capacity to provide informed consent\n\nExclusion Criteria:\n\n* Mechanical ventilation\\* or non-invasive positive pressure ventilation administered for respiratory insufficiency prior to the time of informed consent\n* Delirium (positive CAM screening) at the time of informed consent\n* Ocular trauma, which may interfere with the mechanism of action\n* Traumatic brain injury (TBI) or history of TBI or stroke, which may interfere with the mechanism of action\n* Splenectomy upon admission or history of splenectomy, which may interfere with the mechanism of action\n* History of significant ocular dysfunction\\*\\* (i.e., macular degeneration, glaucoma, cataracts), which may interfere with the mechanism of action\n* History of cataract surgery, due to the possibility of blue light filtering intraocular lens placement\n* History of bipolar disorder or schizophrenia, which could increase the risk of an adverse reaction to light exposure (i.e., acute mania)\n* History of dementia, which would compromise the reliability of pain intensity and delirium measures\n\n  * Or other condition in which a patient cannot open eyes to receive light intervention or report a pain score \\*\\*Myopia, hyperopia, and\u002For astigmatism corrected for with contact lenses or spectacle corrective eyeglasses will NOT be a criterion for exclusion",{"count":227,"type":21},75,[24],"The main goal of this clinical trial is to learn if light therapy improves pain and inflammation in adults with painful rib fractures. The main question it aims to answer is:\n\n\\- Does bright blue light therapy in addition to standard pain treatments improve pain with breathing in adults with painful rib fractures?\n\nResearchers will compare participants who receive bright blue light therapy to participants who receive white light therapy and participants who receive only usual lighting conditions to look for differences in their pain control. In addition to their assigned light treatment, all participants will receive standard pain control treatments.\n\nParticipants will be assigned randomly to one of three groups: one-third will be assigned to bright blue light therapy, one-third will be assigned to bright white light therapy, and one-third will be assigned to usual light only. They will receive their assigned light treatment for 4 hours during the morning\u002Fearly afternoon for up to 3 days while they are in the hospital. On each day they receive the light treatment and on the day after their final light treatment:\n\n* They will be asked twice to rate their pain at rest and with taking a deep breath.\n* They will be tested to confirm that they are not experiencing delirium, or confusion related to being in the hospital.\n* Blood samples will be collected to look for changes in inflammation and the circadian clock, the body's natural 24-hour cycle.",[231,27],"Rib Fractures",[233,234,235,236,237,238],"Light Therapy","Blue Light Therapy","Pain Control","Analgesia","Immunomodulation","Bright Light Therapy","2026-03-02",{"date":241,"type":33},"2026-03-04",{"date":243,"type":33},"2024-10-23",{"date":245,"type":21},"2026-08",{"name":247,"class":40},"Rebecca E Kotcher, MD",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":133,"sex":17,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":41},"100618768","phase-1-phase-1-study-of-sbs-147-in-healthy-adults-100618768","NCT07335913","Phase 1 Study of SBS-147 in Healthy Adults","A PHASE 1, TWO-PART, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF ORALLY ADMINISTERED SBS-147 IN HEALTHY ADULTS","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form (ICF)\n2. Healthy adult male or female, aged 18 to 55 years, inclusive, at Screening\n3. Body mass index (BMI) within 18.0 kg\u002Fm2 to 32.0 kg\u002Fm2 inclusively\n4. Minimum body weight of at least 50.0 kg at Screening\n5. Stated willingness to comply with all study procedures and availability for the duration of the study\n6. Females of childbearing potential\n7. Healthy, as determined by protocol requirements\n8. Non- or ex-smoker for at least 90 days prior to Screening\n9. Participant is able and willing to comply with all study protocol procedures and requirements\n\nExclusion Criteria:\n\n1. Female who is lactating at Screening\n2. Female who is pregnant\n3. History of significant hypersensitivity reactions (like angioedema) to any drugs\n4. Presence or history of significant surgery that may affect drug bioavailability\n5. History of significant CV, pulmonary, hematologic, neurologic, psychiatric, endocrine, infectious, or immunologic disease\n6. Meet Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria for lifetime or current substance use disorder for any psychoactive substances other than nicotine or caffeine\n7. Showing suicidal tendency as per the C-SSRS administered at screening and clinic admission\n8. Any clinically significant illness in the 28 days prior to the first study drug administration\n9. Use of any prescription drugs in the 28 days or 5 half-lives, whichever is longer, prior to Screening and until the end of the study, that in the opinion of an Investigator would put into question the status of the participant as healthy\n10. Use of opioids, hypnotics, and\u002For sedatives in the last 30 days prior to screening\n11. Routine or chronic use of acetaminophen or nonsteroidal anti-inflammatory drugs for more than 7 of the 20 days during the screening period.\n12. Use of St. John's Wort in the 28 days prior to Screening\n13. Use of any herbal supplements (including Kratom) the 14 days prior to Screening\n14. Intake of an Investigational Product (IP) in the 30 days prior to Screening\n15. Positive test result for alcohol and\u002For drugs of abuse at Screening or prior to the first drug administration\n16. Positive screening results to HIV Ag\u002FAb combo, hepatitis B surface antigen or hepatitis C virus Ab tests\n17. Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of an Investigator and based on clinical judgment, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data\n18. Donation of plasma in the 7 days prior to Screening\n19. Donation of 1 unit of blood to American Red Cross or equivalent organization or donation of over 500 mL of blood in the 56 days prior to Screening\n20. Inclusion in a previous cohort for this clinical study\n21. Supine pulse rate less than 45 beats per minute (bpm) or more than 100 bpm at the screening visit\n22. Supine systolic blood pressure \\\u003C 90 or \\> 140 mmHg or diastolic blood pressure \\\u003C 40 or \\> 90 mmHg at the Screening visit\n23. Oxygen saturation (SpO2) below 95% at the Screening visit\n24. Presence of out-of-range cardiac interval on the ECG at screening or other clinically significant ECG abnormalities, unless deemed non-significant by an Investigator\n25. History of risk factors for Torsades de Pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalaemia, hypercalcaemia, or hypomagnesaemia\n26. Family history of long QT syndrome or Brugada syndrome\n27. History of fainting\n28. Family history of sudden cardiac death or significant heart disease\n29. Known presence or history of gastroesophageal reflux or hiatal hernia","55 Years",{"count":257,"type":21},80,[259],"PHASE1","This study is part of the HEAL Initiative supported by the NIH.\n\nThe purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147.\n\nSome participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results.\n\nThe study includes two parts:\n\nSingle-Dose Group, where Participants receive SBS-147 or placebo one time.\n\nMultiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.",[60,59],[263,264,265,266,267,268,269],"Arylepoxamide","AEAr Agonist","6TM","Tolerability","Safety","SBS-147","SBS147","2026-02-27",{"date":272,"type":33},"2026-03-03",{"date":274,"type":33},"2026-01-08",{"date":276,"type":21},"2027-02-28",{"name":278,"class":279},"Sparian Biosciences, Inc","INDUSTRY",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},"100539618","effect-of-vitamin-c-on-pain-reduction-after-an-emergency-department-visit-100539618","NCT06306183","Effect of Vitamin C on Pain Reduction After an Emergency Department Visit","Vitamin C for Acute Musculoskeletal Pain in Emergency Department Patients: A Triple-Blind Randomized Control Trial (VICAMED)","Vicamed","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Presenting to the ED with acute MSK pain of ≤ 48 hours duration at triage\n3. Verbal numerical rating scale pain intensity at triage of ≥ 4 on a 0-10 scale\n4. Triaged to the ambulatory section of the ED\n5. Able to communicate in French or English\n\nExclusion Criteria:\n\n1. Usage of Vit C supplements in the last week\n2. Active cancer\n3. Treated with opioids for any pain within 24 hours prior to recruitment\n4. Treatment for chronic pain\n5. Unable to fill out a pain intensity diary or unavailable for follow-up\n6. Allergy to milk (lactose in the placebo) or Vit C\n7. Treated with cyclosporine or warfarin\n8. Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis\n9. Hospitalized after clinician evaluation",{"count":289,"type":21},204,[24],"Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. Because of these limits, some patients receive opioids, which can cause side effects and carry a risk of dependence. Safer and more accessible options are needed.\n\nVitamin C is widely known for supporting the immune system, but research suggests it may also help reduce pain and inflammation. Studies in surgical patients have shown that vitamin C can lower pain levels, reduce the need for opioids, and support healing. These effects may be linked to its antioxidant properties and its role in tissue repair. However, no study has tested whether vitamin C can help people with recent MSK injuries treated in the emergency department.\n\nThe VICAMED study aims to answer this question. Adults arriving with an MSK injury that occurred within the past 48 hours can participate if they have at least moderate pain. Participants are randomly assigned to receive either vitamin C or a placebo. The first dose is given in the emergency department, followed by twice daily capsules for three days. Pain is measured using a simple 0-100 scale, recorded in an electronic or paper diary. A follow-up on day six helps the research team understand each participant's recovery, medication use, and overall experience.\n\nVitamin C is inexpensive, widely available, and very safe at the doses used in this study. If it proves effective, it could offer a simple, low risk option to help patients manage pain after an MSK injury and reduce the need for opioids in emergency care.",[27],[206,294,208,59,295],"NSAID","RCT",{"date":239,"type":33},{"date":298,"type":33},"2025-09-01",{"date":300,"type":21},"2029-12",{"name":217,"class":40},4,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":50,"minAge":311,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":41},"100536367","stellate-ganglion-block-for-prevention-of-post-mastectomy-depression-100536367","NCT06263907","Stellate Ganglion Block for Prevention of Post Mastectomy Depression","Preemptive Efficacy of Stellate Ganglion Block for Prevention of Post Mastectomy Depression","SGB","Inclusion Criteria:\n\n* Female patients\n* Age ranging from 18 to 65 years\n* American Society of Anesthesiologists (ASA) no more than II\n* Had unilateral cancer breast\n* Scheduled to do unilateral modified radical mastectomy\n\nExclusion Criteria:\n\n* Pregnant female\n* Existing Horner syndrome\n* Had any neuromuscular disease\n* Had allergy to local anesthetics\n* History of use of analgesics\n* Had any deformity or a previous surgery in the neck or ipsilateral arm or breast\n* Had any contraindication to the procedure (coagulation disorders, local infection, sepsis)\n* Had any contraindication to the sympathetic blockade (decompensate cardiopulmonary or hemodynamic disorders)\n* History of psychotic disorder including depression, bipolar disorder or personality disorder\n* Patient with Beck Depression Inventory (BDI) score more than 13","21 Years","65 Years",{"count":314,"type":21},140,[24],"Complications after mastectomy include chronic pain and depression.",[318,27,319],"Mastectomy","Pain, Chronic","2026-02-15",{"date":322,"type":33},"2026-02-17",{"date":324,"type":33},"2024-03-01",{"date":326,"type":21},"2028-12-30",{"name":328,"class":40},"Mansoura University",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":344,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":41},"100624575","combined-acupressure-effects-on-post-thoracotomy-pain-and-lung-volume-100624575","NCT07411417","Combined Acupressure Effects on Post-Thoracotomy Pain and Lung Volume","The Effects of Acupressure Combination on Post-Thoracotomy Pain and Lung Volume During Rest, Breathing-Coughing Exercises: A Randomized Controlled Study","Inclusion Criteria:\n\n* Underwent thoracotomy\n* Undergoing thoracic surgery for the first time\n* Classified as ASA (American Society of Anesthesiology) physical status I, II and III\n* Presence of a drain upon admission to the intensive care unit\n* Conscious, oriented, and cooperative\n* Provided verbal and written informed consent after receiving information about the study\n\nExclusion Criteria:\n\n* Intubated\n* Persistent anxiety before the surgery\n* Diagnosed with panic disorder\n* Chemotherapy within the last 6 months\n* Diagnosed psychiatric illness or mental health problems\n* Presence of edema\n* Intraoperative or postoperative complications\n* Non-Turkish speaking, or presence of hearing or visual impairment\n* Body mass index (BMI) greater than 30\n* Participation in another clinical trial during the study period",{"count":257,"type":21},[24],"Pain is a subjective, sensory and emotionally unpleasant experience resulting from real or hidden injuries in tissues. The pain experience is a subjective and unique experience in physiological and psychological terms and is the first negative sensory experience of the patient after the surgical procedure. Thoracotomy is an invasive surgical incision that causes severe postoperative pain due to the negative effect on the ribs, muscles and peripheral nerves. During thoracic surgery, anatomical lung resection is performed through posterolateral thoracotomy. Surgical incision during thoracotomy surgery is the most severe cause of postoperative pain. Epidural analgesia, peripheral nerve block and systematic treatment methods are used in post-thoracotomy pain management. Opioid use is frequently preferred in post-thoracotomy pain management. Although thoracotomy pain can mostly be controlled with opioid analgesics, excessive use of opioids may lead to respiratory suppression, constipation, suppression of cough, nausea, vomiting and many other possible side effects. Ineffective postoperative pain management may lead to postoperative complications such as increased cardiac workload, prolonged pulmonary rehabilitation and delayed wound healing. The use of holistic non-drug pain relief methods is vital in reducing the need for opioid analgesics and the risk of possible side effects in early postoperative pain management.",[27,340,341,342,343],"Breathing, Mouth","Relaxation; Diaphragm","Cough","Lung Volume",[345,346,59,343],"Thoracotomy after Pain","Acupressure","2026-02-11",{"date":349,"type":33},"2026-02-13",{"date":351,"type":33},"2025-01-06",{"date":353,"type":21},"2027-01-06",{"name":355,"class":40},"Özgül Aydemir",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":41},"100612149","phase-2-a-randomized-comparison-between-067-mcgkg-1-mcgkg-and-133-mcgkg-of-perineural-dexmedetomidine-for-ultrasound-guided-infraclavicular-block-100612149","NCT07249827","A Randomized Comparison Between 0.67 mcg\u002Fkg, 1 mcg\u002Fkg, and 1.33 mcg\u002Fkg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block","Inclusion Criteria:\n\n* patients undergoing upper limb surgery at or below the elbow\n* age between 18 and 75 years\n* American Society of Anesthesiologists classification 1-3\n* body mass index between 18 and 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* adults who are unable to give their own consent\n* allergy or contraindication to dexmedetomidine\n* exposure to dexmedetomidine during the previous 48 hrs\n* pre-existing neuropathy (assessed by history and physical examination)\n* coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood workup i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or partial prothrombin time ≥ 50)\n* renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work-up i.e. creatinine. eGFR \\\u003C 90)\n* hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work-up i.e. transaminases ≥ 100)\n* allergy to LA\n* pregnancy (as institutional policy, female patients with childbearing potential undergoing non urgent surgery are tested preoperatively for pregnancy with blood tests)\n* breast feeding\n* prior surgery in the infraclavicular region\n* chronic pain syndromes requiring opioid intake at home","75 Years",{"count":364,"type":21},69,[366],"PHASE2","This study will compare three different doses of perineural dexmedetomidine 0.67 mcg\u002Fkg, 1 mcg\u002Fkg, and 1.33 mcg\u002Fkg as adjuvants to local anesthetics for ultrasound-guided infraclavicular brachial plexus blocks (ICBs). Our research hypothesis is that 1.33 mcg\u002Fkg will provide a 15%-longer duration than 1mcg\u002Fkg, which in turn will provide a 15%-longer duration than 0.67 mcg\u002Fkg. Since analgesic duration and sensory duration can be influenced by intake of pain medications and surgical trauma to small cutaneous nerves, respectively, we will select motor block duration as the main outcome to better target the action of dexmedetomidine on the brachial plexus.",[236,27,369,370],"Upper Extremity Surgery","Nerve Block",[236,372,373,374,375,376],"Acute pain","Brachial plexus","Brachial plexus block","Postoperative pain","Nerve block","2026-01-04",{"date":379,"type":33},"2026-01-07",{"date":381,"type":33},"2025-12-28",{"date":32,"type":21},{"name":384,"class":40},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":133,"sex":17,"minAge":392,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":396,"conditions":397,"keywords":403,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":41},"100396242","fmri-and-ivcm-cornea-microscopy-of-cxl-in-keratoconus-100396242","NCT04439552","fMRI and IVCM Cornea Microscopy of CXL in Keratoconus","Neuroplasticity of Pain Pathways and Corneal Afferent Regeneration Following Corneal Crosslinking (CXL) in Keratoconus","Inclusion Criteria:\n\nCXL Group\n\n* Age 8-35 years\n* Clinical diagnosis of keratoconus and seeking CXL treatment\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nControl Group\n\n* Age 8-35 years\n* No diagnosis of keratoconus\n* English speaking ability sufficient to comprehend consent with parental assistance\n* MRI compatible\n* Ability to lie still for an MRI session (60 minutes)\n\nExclusion Criteria (Both Groups):\n\n* Claustrophobic\n* Weight \\> 285 lbs (weight limit of the MRI table)\n* Significant medical history, including:\n\nCurrent DSM-IV-TR axis I psychiatric disorders. Chronic pain Significant head injury Seizures Brain tumor Cerebrovascular accident Neurological disease aside from migraine HIV-AIDs Prescription medication strongly implicated in causing dry eyes\n\n* Magnetic implants or metal-containing tattoos on their chest or above\n* Pregnancy\n* History of contact lens wear\n* Any allergic response to a numbing eyedrop in the past","8 Years","35 Years",{"count":395,"type":21},60,"Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).",[184,319,27,398,399,400,401,402],"Surgical Injury","Surgical Wound","Cornea Injury","Cornea","Keratoconus",[404,405,406,407],"fMRI","Corneal Microscopy","IVCM","Neuroimaging","2025-12-15",{"date":410,"type":33},"2025-12-19",{"date":412,"type":33},"2021-10-04",{"date":414,"type":21},"2027-12",{"name":416,"class":40},"Boston Children's Hospital",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":302},"100612541","three-brief-psychological-interventions-for-acute-pain-in-inpatients-in-boyac-100612541","NCT07254923","Three Brief Psychological Interventions for Acute Pain in Inpatients in Boyacá","Three Brief Psychological Interventions for Acute Pain in Inpatients in Boyacá: Randomized Three-Arm Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Admitted to short-stay inpatient or emergency observation units at participating hospitals (same index admission).\n* Acute pain ≤7 days with baseline pain ≥4\u002F10 on a 0-10 numeric\u002Fvisual scale.\n* Clinically stable and able to remain at bedside for \\~30-40 minutes (consent, baseline, single session, post-session assessment).\n* Analgesic regimen stable ≥1 hour before baseline pain rating (no planned change during the \\~20-minute study window unless clinically required).\n* Able to understand simple instructions and communicate pain ratings (verbal or pointing) and to provide written informed consent.\n\nExclusion Criteria:\n\n* Cancer-related pain or chronic pain \\>6 months (e.g., widespread musculoskeletal pain\u002Ffibromyalgia).\n* Active inflammatory\u002Fdegenerative rheumatic disease causing ongoing daily pain that would confound acute pain ratings (e.g., rheumatoid arthritis flare, advanced osteoarthritis, severe osteoporosis-related pain).\n* Cognitive impairment\u002Fdementia, delirium, or acute severe psychiatric disturbance that prevents consent or reliable self-report.\n* Respiratory conditions that contraindicate slow deep-breathing rescue (e.g., decompensated COPD, acute asthma, need for high-flow oxygen or ventilatory support).\n* Hemodynamic or clinical instability (e.g., need for urgent procedure; in resuscitation\u002Freanimation area; RASS ≤ -3; MAP \\\u003C65 mmHg or SBP \\\u003C90 mmHg; SpO₂ \\\u003C90% despite usual oxygen) at screening.\n* Participation in another interventional study targeting pain during the same admission.\n* Refusal to participate or withdrawal of consent.","90 Years",{"count":426,"type":21},160,[24],"This study evaluates two brief, non-drug psychological techniques-body-scan mindfulness and guided imagery\u002Fdistraction-delivered as a single bedside session to reduce acute pain in adults admitted to short-stay inpatient wards or emergency observation units in Boyacá, Colombia. Participants are randomly assigned (1:1:1) to body-scan mindfulness, guided imagery\u002Fdistraction, or a brief cognitive-behavioral psychoeducation session (active comparator). Each session lasts under 20 minutes and usual medical care continues. Pain intensity (0-10) is recorded within 5 minutes before the session and within 2 minutes after completion on the same day. If pain remains very high (e.g., ≥8-9\u002F10) or the activity cannot be completed, up to 5 minutes of supervised slow deep-breathing may be offered as rescue, and the clinical team may adjust analgesics per routine care. Secondary measures (specified in Outcome Measures) include patient satisfaction, feasibility (session duration and completion), use of rescue measure, and adverse events; exploratory data may include short-term psychological scales collected by a blinded assessor and the association with length of stay during the current admission. Adults aged ≥18 years with acute pain ≤7 days and baseline pain ≥4\u002F10 may be eligible. The study takes place across four public hospitals in Boyacá, Colombia.",[430,60],"Pain Management",[432,433,434,435,436,437,430,438,439],"body scanning","ABC","Guided Imagery","Breathing Exercises","Acute Pain","Pain Measurement","Inpatients","Randomized Controlled Trial","2025-11-19",{"date":442,"type":33},"2025-11-28",{"date":444,"type":21},"2026-01",{"date":446,"type":21},"2026-12-16",{"name":448,"class":40},"Universidad Pedagógica y Tecnológica de Colombia",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":133,"sex":17,"minAge":18,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":461,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":41},"100547686","exploration-of-gait-biomechanics-and-muscle-pain-of-the-lower-extremity-100547686","NCT06411197","Exploration of Gait Biomechanics and Muscle Pain of the Lower Extremity","Inclusion Criteria:\n\n* Healthy men and women aged 18-45 years\n\nExclusion Criteria:\n\n* Pregnancy\n* Drug addiction, defined as the use of cannabis, opioids, or other drugs\n* Previous or current neurologic or musculoskeletal illnesses\n* Current pain\n* Lack of ability to cooperate","45 Years",{"count":457,"type":21},36,[24],"This interventional study aims to test gait biomechanics in healthy individuals with and without experimental muscle pain in the lower extremities. The study aims to:\n\nA) Examine how experimental muscle pain in different types of muscles (ankle plantar-flexion, knee extension, and flexion muscles) affects kinematics, kinetics, and muscle activation\n\nParticipants will receive six muscle injections: a) Hypertonic saline (painful condition) and b) Isotonic saline (control condition) in 1) m. gastrocnemius, 2) m. semitendinosus, and 3) m. biceps femoris.",[27],[462,463,464],"Musculoskeletal pain","Healthy Participants","Biomechanics","2025-09-30",{"date":467,"type":33},"2025-10-02",{"date":469,"type":33},"2023-11-08",{"date":471,"type":21},"2026-12-31",{"name":473,"class":40},"Kristian Kjær Petersen",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":41},"100505741","ultrasound-guided-percutaneous-intercostal-nerve-cryoneurolysis-for-analgesia-following-traumatic-rib-fracture-100505741","NCT05865327","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture, a Pilot Randomized Control Trial (UNPIN Trial)","UNPIN","Inclusion Criteria:\n\n* Aged ≥18\n* Unilateral traumatic rib fractures (3 to 8)\n* Candidate for ESP block catheter\n* Within 48hrs of admission to hospital\n\nExclusion Criteria:\n\n* Lack of patient consent; unlikely to comply with follow up\n* Unable to use Patient Controlled Regional Analgesia (Ventilated\u002Fsedated patients or Moderate to severe traumatic brain injury)\n* Chronic pain (opioid use \\> 30mg oral morphine equivalent per day)\n* Substance use disorder\n* CrCl \\\u003C 50\n* BMI \\> 45\n* Significant distracting injuries (unreduced long bone fractures, unstable pelvic or spine fractures and patients requiring trauma laparotomy- also preclude positioning for block placement (lateral decubitus or sitting up))\n* Contraindications for ESP catheter placement (pre-existing medical\u002Fneurological\u002Fhematologic diseases, localized infection\u002Ftrauma at site of intervention, allergy to amide local anesthetics)\n* Contraindications to CN (cryoglobulinemia, paroxysmal cold hemoglobinuria, multiple myeloma and cold urticarial).\n* Unable to return to Trauma Recovery Clinic (in-person or virtual) at 3 months","100 Years",{"count":484,"type":21},24,[24],"Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life.\n\nA technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.",[231,488,489,59,27,319,490,491],"Rib Fracture Multiple","Rib; Fracture, With Flail Chest","Trauma","Trauma Injury",[493,494,495],"Cryoneurolysis","Rib Fracture Pain","Intercostal Nerve Block","2025-09-05",{"date":498,"type":33},"2025-09-12",{"date":500,"type":33},"2023-10-23",{"date":502,"type":21},"2025-12",{"name":504,"class":40},"Sunnybrook Health Sciences Centre",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":41},"100604016","butyrate-and-taurine-for-chronic-postsurgical-pain-in-adult-cardiac-surgical-patients-100604016","NCT07144033","Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients","Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients: Bayesian Optimized Double-blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18 or older\n* elective surgery\n* coronary artery bypass graft (CABG), valve repair\u002Freplacement, combined CABG\u002Fvalve procedure, or major aortic procedure via sternotomy\n\nExclusion Criteria:\n\n* emergency surgery\n* redo surgery\n* history of chronic pain or on chronic opioids\u002Fsedatives\n* already taking taurine or butyrate prior to enrolment\n* renal failure with estimated glomerular filtration rate \\\u003C30mL\u002Fmin (calculated by Cockcroft-Gault formula)\n* re-operation within 24 hours after surgery\n* intraoperative use of remifentanil\n* inability to provide informed consent.",{"count":513,"type":21},216,[24],"This study is a single-center, phase II, randomized, placebo-controlled, Bayesian-designed, double-blinded trial\n\nGoal and Questions:\n\nThe primary goal is to evaluate if a combination of taurine and butyrate can reduce chronic postsurgical pain (CPSP) in adult cardiac surgical patients. The study also aims to determine if these compounds are safe, effective in perioperative pain control, and feasible for improving postoperative outcomes.\n\nParticipants:\n\nThe study will include adult patients (aged 18 or older) undergoing elective coronary artery bypass graft (CABG), valve repair\u002Freplacement, combined CABG\u002Fvalve, or major aortic procedure via sternotomy. Exclusion criteria include emergency surgery, redo surgery, a history of chronic pain or chronic opioid\u002Fsedative use, and an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin. The target sample size is 216 patients.\n\nIntervention group: Patients will receive 4g of taurine and 4.8g of sodium butyrate orally once daily, starting the day before surgery and continuing for three months post-surgery.\n\nPlacebo group: Patients will receive indistinguishable placebo capsules orally once daily, following the same schedule as the intervention group.\n\nPrimary Outcome: The incidence of chronic postsurgical pain at 3 months,\n\nSecondary Outcomes:\n\nQuality of Recovery Questionnaire (QoR-15) at 72 hours after extubation.\n\nPain scores (NRS) at rest and with movement at 12, 24, 48, and 72 hours post-extubation.\n\nPostoperative morphine requirements and time to first morphine rescue.\n\nIncidence of opioid-related side effects, such as postoperative nausea and vomiting (PONV).\n\nDuration of mechanical ventilation, and length of stay in the ICU and hospital.\n\nLong-term pain assessment using the Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), Brief Pain Inventory (BPI) Interference Scale, and Neuropathic Pain Questionnaire (NPQ) at 1, 3, 6, and 12 months post-surgery\n\nProteomic analysis:\n\nBlood samples within 72 hours after surgery will be collected for proteomic analysis to investigate predictors for chronic postsurgical pain.",[27,319,517],"Chronic Post Operative Pain","2025-08-28",{"date":496,"type":33},{"date":521,"type":21},"2026-01-01",{"date":523,"type":21},"2028-01-31",{"name":125,"class":40},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":532,"maxAge":18,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":535,"briefSummary":537,"conditions":538,"keywords":545,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":556,"locationsCount":41},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":534,"type":21},78,[536],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[539,27,540,541,542,543,544],"Pancreatitis, Acute","Pancreatic Disease","Pancreatic Diseases","Gastroenterology","Pancreatitis","Paediatrics",[546,547,548,549],"acute pancreatitis","acute pain","painkillers","pancreatitis","2025-08-18",{"date":552,"type":33},"2025-08-24",{"date":554,"type":21},"2025-09",{"date":72,"type":21},{"name":557,"class":40},"Medical University of Warsaw",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":41},"100593708","impact-of-virtual-reality-in-cardiac-electrophysiology-100593708","NCT07009951","Impact of Virtual Reality in Cardiac Electrophysiology","Acute Clinical Outcomes Following the Implementation of Virtual Reality (VR) in the Electrophysiology Laboratory","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients who are candidates for pacemaker (PM) or implantable cardioverter-defibrillator (ICD) implantation, including new devices such as leadless PM and subcutaneous ICD (S-ICD).\n* Ability to provide written informed consent.\n* Ability to understand the use of the VR headset and express a pain score using the NRS scale.\n\nExclusion Criteria:\n\n* Severe cognitive, psychiatric or neurological disorders that impair understanding or collaboration in the study.\n* Visual and\u002For auditory and inner ear disorders or severe vertigo that could be aggravated by VR.\n* Allergies or known adverse reactions to standard sedative therapies provided for in the protocol (e.g. midazolam) if essential for the procedure.\n* Inability to correctly position the VR headset (e.g. severe facial deformities, recent trauma to the craniofacial area).",{"count":52,"type":21},"Pain during pacemaker or defibrillator implantation can increase patient discomfort, anxiety, and the need for deeper sedation. Using virtual reality (VR) as a non-pharmacological distraction tool may help reduce perceived pain, stabilize vital signs, and improve the overall patient experience. This prospective, single-center study evaluates whether adding VR to standard sedation lowers pain levels compared to sedation alone. Patients undergoing device implantation will be randomized to either group, with pain and vital signs monitored throughout the procedure. The study also explores patient satisfaction, adverse effects, and the potential of VR to support same-day discharge after minimally invasive procedures.",[27],"2025-08-06",{"date":570,"type":33},"2025-08-07",{"date":572,"type":33},"2025-07-01",{"date":574,"type":21},"2025-12-31",{"name":576,"class":40},"University of Calabria",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":586,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":41},"100596673","perioperative-intravenous-nimodipine-trial-100596673","NCT07048522","Perioperative Intravenous Nimodipine Trial","Perioperative Nimodipine for Intra- and Postoperative Pain Management and Reduction of Anesthetic Requirements in Patients Undergoing Open Colectomy: a Prospective, Double-blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled for open surgical treatment of bowel cancer at the General Hospital of Patra\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years, \\> 75 years\n* American Society of Anesthesiologists (ASA) physical status \\> III\n* Allergy to nimodipine\n* Inability to provide informed consent\n* Known severe renal insufficiency\n* Known severe bradyarrhythmia\n* Daily opioid consumption the last 7 days before surgery\n* Pain intensity assessed using the Numerical Rating Scale (NRS; 0-10), with scores greater than 5 reported on more than half of the days during the past month.",{"count":585,"type":21},40,[24],"The role of perioperative IV administration of nimodipine, an L-type calcium channel antagonist which is capable of crossing the blood-brain barrier, on peri-operative opioid and anesthetics requirements, pain intensity, opioid-related side effects and early postoperative bowel mobility in patients undergoing surgical treatment for bowel cancer with open radical colectomy remains scarcely explored. A prospective double-blind, randomized controlled trial investigating the effect of perioperative IV administration of nimodipine in patients undergoing open colectomy for cancer treatment is therefore conducted.",[589,590,59,184,27],"Colectomy","Open Surgery","2025-06-30",{"date":593,"type":33},"2025-07-02",{"date":595,"type":33},"2025-05-19",{"date":597,"type":21},"2027-02-15",{"name":599,"class":40},"University of Ioannina",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":133,"sex":50,"minAge":18,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":41},"100589892","empathy-through-pain-control-lidocaine-paracervical-block-for-iud-placements-100589892","NCT06960317","Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements","Expanding the Use of Paracervical Block for IUD Placements and Adding a Compassionate Care Assessment","EPIC","Inclusion Criteria:\n\n1. Ability to provide informed consent\n2. Women IUD placement for contraception or heavy menstrual bleeding\n3. Ages 18-50\n4. English-speaking\n5. Participants must not have a past medical history of substance use disorders, pain disorders, use of prescription pain medications or are found to be pregnant\n\nExclusion Criteria:\n\n1. No history of vaginal delivery\n2. Current use of prescription pain medication prior to procedure. Over-the-counter medications such as those containing ibuprofen, aspirin, acetaminophen, or naproxen are allowed.\n3. Diagnosed chronic pain condition\n4. Current pregnancy\n5. Known allergic reactions to components of the local anesthetic\n6. History of an IUD placement\n7. Current substance use or history of substance use\n8. Known contraindications to IUD, such as unexplained vaginal bleeding","50 Years",{"count":289,"type":21},[24],"The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy.\n\nThe investigators are inviting patients who arrive at their clinic visit seeking an IUD.\n\nUsually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a \"buffered\" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.",[613,27,614],"Contraception","Anesthesia, Local","2025-06-10",{"date":617,"type":33},"2025-06-13",{"date":619,"type":33},"2025-06-04",{"date":621,"type":21},"2028-06-30",{"name":623,"class":40},"University of California, San Diego",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":133,"sex":50,"minAge":631,"maxAge":608,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":633,"briefSummary":634,"conditions":635,"keywords":638,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":649,"locationsCount":41},"100534548","tens-unit-for-analgesia-during-iud-insertion-100534548","NCT06240260","TENS Unit for Analgesia During IUD Insertion","Utilization of Transcutaneous Electrical Nerve Stimulation (TENS) Unit for Analgesia During IUD Insertion: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Persons with a uterus desiring insertion of intrauterine device\n2. Able to provide informed consent\u002Fassent\n3. Age 12-50 years old\n4. Minors 12 years of age and older will be included in the study if postmenarchal\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\u002Fassent\n2. Prior cervical procedure (ie loop electrosurgical excision procedure, LEEP)\n3. Concurrent cervical or intrauterine procedure (ie colposcopy or dilation and curettage)\n4. Cutaneous damage at the TENS electrode sites\n5. Chronic or pre-procedure use of opioids\n6. Chronic pain diagnosis\n7. Prior IUD insertion\n8. Any contraindication to intrauterine device (IUD):\n\n   1. Pregnancy\n   2. Uterine anomaly that distorts the uterine cavity\n   3. Acute pelvic inflammatory disease (PID)\n   4. Postpartum endometritis or infected abortion in the past 3 months\n   5. Unexplained abnormal uterine bleeding\n   6. Wilson's disease or copper allergy (contraindication to copper IUD only)\n   7. Breast cancer (contraindication to levonorgestrel IUD only","12 Years",{"count":585,"type":21},[24],"Subjects will be screened over the phone or in Tufts GYN clinic for participation in the study. If eligible and interested in participating, written informed consent (and assent if applicable) will be obtained. After informed consent\u002Fassent, the patient will be enrolled in the study. The patient will decide if they desire to use TENS unit during IUD insertion appointment and inform the study team. The clinic visit will proceed as normal, with additional study proceedings as follows. The study personnel will complete the 'Background Questionnaire' with the patient prior to IUD insertion. During the IUD insertion appointment, study personnel will assist in collection of the 'Study visit' data collection form. This includes recording the patient's pain score at various time points throughout the insertion procedure:\n\n* anticipated pain during IUD insertion\n* baseline pain prior to insertion\n* speculum insertion\n* tenaculum placement\n* paracervical block administration (if performed)\n* cervical dilation (if performed)\n* uterine sounding\n* IUD insertion\n* 5 minutes after IUD insertion\n\nStudy personnel will also time the insertion procedure and collect additional data as outlined in the 'Study visit data collection form.' After IUD insertion, the participant will be asked to complete the 'Post-IUD Insertion Survey.' Once this survey is complete, this will conclude the study participation. Participation will last through the study visit only.\n\nAs part of the standard of care, a urine pregnancy test will be obtained and confirmed negative prior to IUD insertion. Patients will receive routine pain management modalities per shared decision-making with their clinical provider which may include NSAID administration, paracervical block, and heating pad.",[636,236,637,27],"IUD","Patient Preference",[639,640,641,642,643],"iud","contraception","iud placement","pain management","teen","2025-06-03",{"date":619,"type":33},{"date":647,"type":33},"2024-04-30",{"date":574,"type":21},{"name":650,"class":40},"Tufts Medical Center",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":22,"phases":662,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":674,"locationsCount":41},"100544104","phase-4-nebulized-ketamine-to-nebulized-fentanyl-for-treating-acute-painful-conditions-in-the-ed-100544104","NCT06364540","Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED","Comparison of Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED: A Prospective, Randomized, Double-Blind Clinical Trial.","KETAFEN","Inclusion Criteria:\n\n* age 18+ years\n* acute painful condition\n* pain score of 5 or more on a standard 11 point numeric rating scale (NRD)\n* patient needs to be awake, alert, and oriented as to person, place, and time\n* demonstrated understanding of the informed consent process and content\n* patient needs to demonstrate the ability to verbalize the nature of any adverse effects (AE)\n* patient needs to experience as well as express their pain severity by using the NRS\n\nExclusion Criteria:\n\n* patient with a painful condition warranting emergent\u002Furgent intervention in the ED\n* patients with altered mental status\n* allergy to ketamine or fentanyl\n* pregnant or breastfeeding\n* weight greater than 100 kg\n* patients presenting with head injury\n* unstable vital signs (systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg, pulse rate \\\u003C50 beats\u002Fmin or \\>150 beats\u002Fmin, and respiration rate \\\u003C10 breaths\u002Fmin or \\>30 breaths\u002Fmin)\n* inability to provide consent\n* current medical history of alcohol or drug abuse\n* administration of opioids or opioid antagonist\u002Fagonist within 4-6 hours prior to arrival and NSAIDs 6 hours prior to arrival to the t","120 Years",{"count":661,"type":21},150,[536],"In situations where intravenous access is not readily available or is unobtainable and the intranasal route is not feasible, another non-invasive route of ketamine administration, such as inhalation via breath-actuated Nebulizer (BAN), is becoming a viable alternative. The BAN allows the controlled, patient-initiated delivery of analgesics in a measured and titratable fashion. (18) Ketamine has been studied as a nebulized drug in a lot of different settings and for a lot of different reasons, such as to treat acute pain after surgery (like a sore throat after being intubated), as a pre-medication for general anesthesia, to treat cancer pain, and as a therapy for asthmaticus.\n\nOur research team has published two case series of 10 adult patients who were given nebulized ketamine (via BAN) for a variety of acute traumatic and non-traumatic painful conditions. The patients showed a 60% decrease in pain and a small number of side effects. Furthermore, our group published a randomized, double-blind trial of 120 adult patients evaluating the analgesic efficacy and safety of nebulized ketamine at three different dosing regimens for acute pain in the ED (0.75 mg\u002Fkg, 1 mg\u002Fkg, and 1.5 mg\u002Fkg), showing similar analgesic efficacy between the three different dosing regimens for short-term (up to 120 minutes) pain relief. Lastly, we recently completed a randomized, double-blind, double-dummy clinical trial comparing the analgesic efficacy and safety of nebulized ketamine and intravenous ketamine in managing acute pain in adult ED patients, with data currently being analyzed.\n\nNebulized fentanyl given in the ED to adults with acute traumatic and non-traumatic pain syndromes at a dose range of 1.5-4 mcg\u002Fkg showed the same or even better pain-relieving effects than IV fentanyl and IV morphine alone.\n\nOur objective is to compare the analgesic efficacy and rates of side effects of a 0.75 mg\u002Fkg dose of ketamine administered via breath-actuated nebulizer (BAN) to a dose of 3 mcg\u002Fkg of fentanyl administered via breath-actuated nebulizer (BAN) in adult patients presenting to the ED with acute painful conditions.",[27],[63,666,667,668],"acute","emergency medicine","clinical tiral","2025-05-30",{"date":619,"type":33},{"date":672,"type":33},"2024-05-01",{"date":471,"type":21},{"name":675,"class":40},"Antonios Likourezos"]